0001193125-24-136782.txt : 20240513 0001193125-24-136782.hdr.sgml : 20240513 20240513090039 ACCESSION NUMBER: 0001193125-24-136782 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scilex Holding Co CENTRAL INDEX KEY: 0001820190 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39852 FILM NUMBER: 24937104 BUSINESS ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: (650) 516-4310 MAIL ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Scilex Holding Company/DE DATE OF NAME CHANGE: 20221117 FORMER COMPANY: FORMER CONFORMED NAME: Vickers Vantage Corp. I DATE OF NAME CHANGE: 20200804 8-K 1 d818587d8k.htm 8-K 8-K
Scilex Holding Co false 0001820190 0001820190 2024-05-13 2024-05-13 0001820190 sclx:CommonStockParValue0.0001PerShare2Member 2024-05-13 2024-05-13 0001820190 sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member 2024-05-13 2024-05-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 13, 2024

 

 

SCILEX HOLDING COMPANY

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39852   92-1062542
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

960 San Antonio Road, Palo Alto, California, 94303

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (650) 516-4310

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.0001 per share   SCLX   The Nasdaq Stock Market LLC
Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share   SCLXW   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 7.01.

Regulation FD Disclosure.

On May 13, 2024, Scilex Holding Company (the “Company”) issued a press release providing information to its stockholders regarding manipulative and naked short selling of shares of its common stock. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

The information under this Item 7.01 of this Current Report is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

   

Description

99.1    Press Release, dated May 13, 2024.
104    Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SCILEX HOLDING COMPANY
By:  

/s/ Jaisim Shah

Name:   Jaisim Shah
Title:   Chief Executive Officer and President

Date: May 13, 2024

 

3

EX-99.1 2 d818587dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO      

FOR IMMEDIATE RELEASE

 

May 13, 2024

Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

 

  •  

Scilex management is determined to enhance its stockholders’ value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.

 

  •  

Of the approximately 181 million shares of Scilex common stock currently issued and outstanding: (a) 76 million were distributed by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) as dividend shares in January 2023 (the “Dividend Shares”) and are restricted from trading until the earlier of (i) September 30, 2024 per court order or (ii) the date on which Sorrento and its Official Committee of Unsecured Creditors agree in writing or on the record in Sorrento’s chapter 11 cases certain claims that may be asserted in potential litigation to avoid Sorrento’s distribution of Dividend Shares and to recover such Dividend Shares; (b) another approximately 60 million shares of Scilex common stock, along with approximately 29 million of shares of Scilex preferred stock, were repurchased by Scilex in September 2023; and (c) approximately 45 million shares of Scilex common stock constitute the unrestricted public float trading on the Nasdaq Capital Market.

 

  •  

According to credible information available to Scilex, Scilex management believes there are approximately 10 million shares of Scilex common stock being sold short and additionally, there are more than 10 million Dividend Shares deemed to have been sold as “naked short” positions on or after January 2023 that have not been covered as of today. The Company believes that there are substantial “naked short” positions in approximately 44 million shares of its common stock that had not cast votes based on the reports tabulated by Broadridge Financial Solutions, Inc., an independent third party that collects and tabulates stockholder votes, for the Company’s prior two annual meetings for its stockholders. This represents a failure by the brokerage firms to deliver the Dividend Shares to the beneficial owner accounts for approximately 15 months constituting a potential violation of Regulation SHO.

 

  •  

Sample letter for Scilex stockholders to send to their brokerage firms to recall loaned shares of Scilex common stock from Brokerages’ Lending Programs.

 

  •  

Sample letter for the beneficial owners, eligible to receive dividend shares of the Company (the “Dividend Shares”) previously distributed by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to its stockholders as a dividend, to demand immediate delivery of the Dividend Shares from such Brokerage Firms as Record Holders.

PALO ALTO, CALIFORNIA – May 13, 2024 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provides information to its stockholders regarding short selling of Scilex common stocks traded on the Nasdaq Capital Market.

 

Page | 1

According to credible information available to Scilex, Scilex management believes there are approximately 10 million share of Scilex common stock being sold short and additionally, there are more than 10 million Dividend Shares deemed to have been sold as “naked short” positions on or after January 2023 that have not been covered as of today. The Company believes that there are substantial “naked short” positions in approximately 44 million shares of its common stock that had not cast votes based on the reports tabulated by Broadridge Financial Solutions, Inc., an independent third party that collects and tabulates stockholder votes, for the Company’s prior two annual meetings for its stockholders. This represents a failure by the brokerage firms to deliver the Dividend Shares for approximately 15 months constituting a potential violation of Regulation SHO.

The practice of manipulative or abusive “naked short” selling or maintaining “naked short” positions may constitute a violation of SEC Regulation SHO.

Scilex Management is determined to combat manipulative and illegal short selling of Scilex common stock which has the effect of reducing shareholder value and infringing on shareholders’ rights. In addition to communicating with regulatory authorities and through the legal processes demanding accurate information pertaining to Scilex stock trades to expose any manipulative and illegal “naked short selling” of Scilex stock, Scilex Management is providing Scilex stockholders with the following information to help combat manipulative short selling or illegal naked short selling or naked short positions in its shares:

Scilex stockholders holding shares on loan in their margin accounts can choose to do the following:

 

  •  

recall their shares from their brokerage firms that administer such lending programs by opting out of any share lending programs;

 

  •  

demand that their shares to be held in a cash account; and/or

 

  •  

move their shares to a Direct Registration (“DRS”) account at the Company’s transfer agent, Continental Stock Transfer & Trust Company.

Sample Letter to Brokerage to Recall Loaned Shares. If a stockholder decides to instruct its brokerage firm not to make their shares of Scilex common stock available for lending, the following is a sample of language that can be used in their communication to the brokerage firm:

 

  •  

Broker name;

 

  •  

Broker address;

 

  •  

Attn: [Agent for Your Account];

 

  •  

Brokerage account number;

 

  •  

The letter should state clearly that the shares of Scilex common stock are to be held in a cash account and should be not made available for any lending programs in the brokerage firm and to not loan any such shares. Additionally, as applicable, there should be a request to recall any such shares that are currently on loan; and

 

  •  

Demand that the brokerage firm confirm the receipt and compliance with such request.

 

Page | 2

Beneficial owners of Dividend Shares, previously distributed by Sorrento to its stockholders as a dividend, can choose to demand their brokerage firms immediately deliver the Dividend Shares to the stockholders’ individual cash brokerage account or to the Company’s transfer agent. A list of the Brokerages that are Record Holders can be found on this link from previously published FAQ.

Sample Letter to Brokerage to Demand Delivery of the Dividend Shares. If a stockholder decides to instruct its brokerage firm, as the Record Holder of such stockholder’s Dividend Shares, to immediately deliver the Dividend Shares to the stockholders’ individual cash brokerage account or to the Company’s transfer agent the following is a sample of language that can be used in their communication to the brokerage firm:

 

  •  

Broker name;

 

  •  

Broker address;

 

  •  

Attn: [Agent for your Account];

 

  •  

Brokerage account number;

 

  •  

The letter should state clearly that you are a beneficial owner of Dividend Shares and you demand immediate delivery of such shares to your individual cash brokerage account or to the Company’s transfer agent from your brokerage firm acting as a Record Holder of these Dividend Shares;

 

  •  

Include the number of Dividend Shares that you were entitled to receive from Sorrento as Dividend Shares by stating how many Sorrento shares you held on January 9, 2023, the record date for receiving Dividend Shares; and

 

  •  

Demand that the brokerage firm confirm the receipt and compliance with your request.

Please note it is not uncommon to provide this written communication to brokerage firm to not lend their clients’ shares for the purpose of short selling. Similar guidance was recently sent out by Trump Media & Technology Group Corp. (Nasdaq: DJT) to its shareholders highlighting actions that its shareholders can take to prevent the lending of their shares by brokerage firms for the purpose of short selling.

Not Investment Advice

The information in this release does not constitute or purport to be investment advice. The Company encourages stockholders to speak with their financial advisors about any transactions and strategies such as using cash accounts to hold their securities instead of margin accounts and the lack of liquidity resulting from or costs of transferring and holding their shares at the Company’s transfer agent to ensure they are appropriate for the stockholders’ individual circumstances.

Additional Information Regarding Moving Shares Out of Brokerage Accounts

Please note that stockholders may incur certain costs in connection with transferring shares out of a brokerage account and, once their shares are moved to our transfer agent, their ability to timely transfer their shares back to a brokerage firm and sell may be a longer process. Holding shares in physical certificate form involves risk of loss or destruction where a bond of indemnity is required to replace the certificate(s).

 

Page | 3

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.

 

LOGO   LOGO   LOGO

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, expected to launch in the first half of 2024.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and has granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which Scilex has recently completed a Phase 2 trial in low back pain. SP-103 has granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022.

Scilex Holding Company is headquartered in Palo Alto, California.

 

Page | 4

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s beliefs of the scale of short selling, lending program activities and market manipulation of its stock price, any potential violations of law and legal challenges with respect to the actions believed to be taken by brokerage firms that are described in this press release, Scilex’s expectation to launch Gloperba® in the first half of 2024.

Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.

Contacts:

Investors and Media

Scilex Holding Company

960 San Antonio

Road Palo Alto, CA 94303

Office: (650) 516-4310

Email: investorrelations@scilexholding.com

 

Page | 5

Website: www.scilexholding.com

# # #

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

All other trademarks are the property of their respective owners.

© 2024 Scilex Holding Company All Rights Reserved.

 

Page | 6

EX-101.SCH 3 sclx-20240513.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 sclx-20240513_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 sclx-20240513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Par Value 0.0001 Per Share 2 [Member] Common Stock Par Value 0.0001 Per Share 2 [Member] Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member] Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member] EX-101.PRE 6 sclx-20240513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g818587g0513071715758.jpg GRAPHIC begin 644 g818587g0513071715758.jpg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end GRAPHIC 8 g818587g0513071716014.jpg GRAPHIC begin 644 g818587g0513071716014.jpg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end GRAPHIC 9 g818587g0513071716200.jpg GRAPHIC begin 644 g818587g0513071716200.jpg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end GRAPHIC 10 g818587g0513071716387.jpg GRAPHIC begin 644 g818587g0513071716387.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 13, 2024
Document And Entity Information [Line Items]  
Entity Registrant Name Scilex Holding Co
Amendment Flag false
Entity Central Index Key 0001820190
Document Type 8-K
Document Period End Date May 13, 2024
Entity Incorporation State Country Code DE
Entity File Number 001-39852
Entity Tax Identification Number 92-1062542
Entity Address, Address Line One 960 San Antonio Road
Entity Address, City or Town Palo Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94303
City Area Code (650)
Local Phone Number 516-4310
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Common Stock Par Value 0.0001 Per Share 2 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol SCLX
Security Exchange Name NASDAQ
Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share
Trading Symbol SCLXW
Security Exchange Name NASDAQ
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 3 23 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d818587d8k.htm 7 d818587d8k.htm sclx-20240513.xsd sclx-20240513_def.xml sclx-20240513_lab.xml sclx-20240513_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 20 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d818587d8k.htm": { "nsprefix": "sclx", "nsuri": "http://www.vickersvantagecorp.com/20240513", "dts": { "inline": { "local": [ "d818587d8k.htm" ] }, "schema": { "local": [ "sclx-20240513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "sclx-20240513_def.xml" ] }, "labelLink": { "local": [ "sclx-20240513_lab.xml" ] }, "presentationLink": { "local": [ "sclx-20240513_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-05-13_to_2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d818587d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-05-13_to_2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d818587d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "sclx_CommonStockParValue0.0001PerShare2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vickersvantagecorp.com/20240513", "localname": "CommonStockParValue0.0001PerShare2Member", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock Par Value 0.0001 Per Share 2 [Member]", "terseLabel": "Common Stock Par Value 0.0001 Per Share 2 [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "sclx_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.vickersvantagecorp.com/20240513", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "sclx_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vickersvantagecorp.com/20240513", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "sclx_WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vickersvantagecorp.com/20240513", "localname": "WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]", "terseLabel": "Warrants To Purchase One Share Of Common Stock Each At An Exercise Price Of 11.50 Per Share 1 [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.vickersvantagecorp.com//20240513/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 21 0001193125-24-136782-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-136782-xbrl.zip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end XML 23 d818587d8k_htm.xml IDEA: XBRL DOCUMENT 0001820190 2024-05-13 2024-05-13 0001820190 sclx:CommonStockParValue0.0001PerShare2Member 2024-05-13 2024-05-13 0001820190 sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf11.50PerShare1Member 2024-05-13 2024-05-13 Scilex Holding Co false 0001820190 8-K 2024-05-13 DE 001-39852 92-1062542 960 San Antonio Road Palo Alto CA 94303 (650) 516-4310 false false false false Common stock, par value $0.0001 per share SCLX NASDAQ Warrants to purchase one share of common stock, each at an exercise price of $11.50 per share SCLXW NASDAQ true true